{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T22:32:03Z","timestamp":1788474723506,"version":"build-2803163510"},"reference-count":60,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,8,10]],"date-time":"2022-08-10T00:00:00Z","timestamp":1660089600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Cardiovasc. Med."],"abstract":"<jats:p>\n                    Barth Syndrome (BTHS) is a rare X-linked mitochondrial disorder due to mutations in the gene\n                    <jats:italic>TAFAZZIN<\/jats:italic>\n                    , which leads to immature cardiolipin (CL) remodeling and is characterized by the development of cardiomyopathy. The immature CL remodeling in BTHS results in electron transport chain respiratory defects and destabilization of supercomplexes, thereby impairing ATP production. Thus, BTHS-related cardiomyopathy appears to share metabolic characteristics of the failing heart being an \u201cengine out of fuel.\u201d As CL associates with numerous mitochondrial enzymes involved in ATP production, BTHS is also characterized by several defects in intermediary energy metabolism. Herein we will describe the primary disturbances in intermediary energy metabolism relating to the heart's major fuel sources, fatty acids, carbohydrates, ketones, and amino acids. In addition, we will interrogate whether these disturbances represent potential metabolic targets for alleviating BTHS-related cardiomyopathy.\n                  <\/jats:p>","DOI":"10.3389\/fcvm.2022.981972","type":"journal-article","created":{"date-parts":[[2022,8,10]],"date-time":"2022-08-10T01:45:36Z","timestamp":1660095936000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":10,"title":["Myocardial disturbances of intermediary metabolism in Barth syndrome"],"prefix":"10.3389","volume":"9","author":[{"given":"Amanda A.","family":"Greenwell","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seyed Amirhossein","family":"Tabatabaei Dakhili","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John R.","family":"Ussher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,8,10]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1016\/0022-510X(83)90209-5","article-title":"An X-linked mitochondrial disease affecting cardiac muscle, skeletal muscle and neutrophil leucocytes","volume":"62","author":"Barth","year":"1983","journal-title":"J Neurol Sci."},{"key":"B2","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1002\/jimd.12422","article-title":"Clinical presentation and natural history of Barth syndrome: an overview","volume":"45","author":"Taylor","year":"2022","journal-title":"J Inherit Metab Dis."},{"key":"B3","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1002\/ajmg.c.31372","article-title":"Barth syndrome","author":"Jefferies","year":"2013","journal-title":"Am J Med Genet C Semin Med Genet."},{"key":"B4","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1007\/s00246-015-1260-z","article-title":"Clinical characteristics and outcomes of cardiomyopathy in Barth syndrome: the UK experience","volume":"37","author":"Kang","year":"2016","journal-title":"Pediatr Cardiol."},{"key":"B5","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1038\/s41436-020-01006-8","article-title":"A phase 2\/3 randomized clinical trial followed by an open-label extension to evaluate the effectiveness of elamipretide in Barth syndrome, a genetic disorder of mitochondrial cardiolipin metabolism","volume":"23","author":"Reid Thompson","year":"2021","journal-title":"Genet Med."},{"key":"B6","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1186\/1750-1172-8-70","article-title":"Natural history of Barth syndrome: a national cohort study of 22 patients","volume":"8","author":"Rigaud","year":"2013","journal-title":"Orphanet J Rare Dis."},{"key":"B7","doi-asserted-by":"publisher","first-page":"144148","DOI":"10.1016\/j.gene.2019.144148","article-title":"TAZ encodes tafazzin, a transacylase essential for cardiolipin formation and central to the etiology of Barth syndrome","volume":"726","author":"Garlid","year":"2020","journal-title":"Gene."},{"key":"B8","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1016\/s1388-1981(02)00329-3","article-title":"Cardiolipin and apoptosis","volume":"1585","author":"Mcmillin","year":"2002","journal-title":"Biochim Biophys Acta."},{"key":"B9","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.chemphyslip.2015.09.005","article-title":"Cardiolipin metabolism and its causal role in the etiology of the inherited cardiomyopathy Barth syndrome","volume":"193","author":"Gaspard","year":"2015","journal-title":"Chem Phys Lipids."},{"key":"B10","doi-asserted-by":"publisher","first-page":"2916","DOI":"10.1074\/jbc.M116.753574","article-title":"Cardiolipin regulates mitophagy through the protein kinase C pathway","volume":"292","author":"Shen","year":"2017","journal-title":"J Biol Chem."},{"key":"B11","doi-asserted-by":"publisher","first-page":"1140","DOI":"10.1056\/NEJMra063052","article-title":"The failing heart\u2013an engine out of fuel","volume":"356","author":"Neubauer","year":"2007","journal-title":"N Engl J Med."},{"key":"B12","doi-asserted-by":"publisher","first-page":"1487","DOI":"10.1161\/CIRCRESAHA.121.318241","article-title":"Cardiac Energy Metabolism in Heart Failure","volume":"128","author":"Lopaschuk","year":"2021","journal-title":"Circ Res."},{"key":"B13","doi-asserted-by":"publisher","first-page":"e13130","DOI":"10.14814\/phy2.13130","article-title":"Impaired cardiac and skeletal muscle bioenergetics in children, adolescents, and young adults with Barth syndrome","volume":"5","author":"Bashir","year":"2017","journal-title":"Physiol Rep."},{"key":"B14","doi-asserted-by":"publisher","first-page":"1649","DOI":"10.1007\/s12350-019-01933-3","article-title":"Myocardial glucose and fatty acid metabolism is altered and associated with lower cardiac function in young adults with Barth syndrome","volume":"28","author":"Cade","year":"2021","journal-title":"J Nucl Cardiol."},{"key":"B15","doi-asserted-by":"publisher","first-page":"1312","DOI":"10.1194\/jlr.M034728","article-title":"Dysfunctional cardiac mitochondrial bioenergetic, lipidomic, and signaling in a murine model of Barth syndrome","volume":"54","author":"Kiebish","year":"2013","journal-title":"J Lipid Res."},{"key":"B16","doi-asserted-by":"publisher","first-page":"12485","DOI":"10.1074\/jbc.RA119.011229","article-title":"Tafazzin deficiency impairs CoA-dependent oxidative metabolism in cardiac mitochondria","volume":"295","author":"Le","year":"2020","journal-title":"J Biol Chem."},{"key":"B17","doi-asserted-by":"publisher","first-page":"H2255","DOI":"10.1152\/ajpheart.00873.2020","article-title":"Barth syndrome-related cardiomyopathy is associated with a reduction in myocardial glucose oxidation","volume":"320","author":"Greenwell","year":"2021","journal-title":"Am J Physiol Heart Circ Physiol."},{"key":"B18","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1002\/jimd.12427","article-title":"Mechano-energetic aspects of Barth syndrome","volume":"45","author":"Dudek","year":"2022","journal-title":"J Inherit Metab Dis."},{"key":"B19","doi-asserted-by":"publisher","first-page":"e108428","DOI":"10.15252\/embj.2021108428","article-title":"Cardiolipin remodeling enables protein crowding in the inner mitochondrial membrane","volume":"40","author":"Xu","year":"2021","journal-title":"EMBO J."},{"key":"B20","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1002\/jimd.12459","article-title":"Long-chain fatty acid oxidation and respiratory complex I deficiencies distinguish Barth Syndrome from idiopathic pediatric cardiomyopathy","volume":"45","author":"Chatfield","year":"2022","journal-title":"J Inherit Metab Dis."},{"key":"B21","doi-asserted-by":"publisher","first-page":"e0128561","DOI":"10.1371\/journal.pone.0128561","article-title":"Cardiac metabolic pathways affected in the mouse model of Barth syndrome","volume":"10","author":"Huang","year":"2015","journal-title":"PLoS ONE."},{"key":"B22","doi-asserted-by":"publisher","first-page":"e008289","DOI":"10.1161\/CIRCHEARTFAILURE.121.008289","article-title":"Cardiolipin remodeling defects impair mitochondrial architecture and function in a murine model of Barth Syndrome cardiomyopathy","volume":"14","author":"Zhu","year":"2021","journal-title":"Circ Heart Fail."},{"key":"B23","doi-asserted-by":"publisher","first-page":"74","DOI":"10.3389\/fphys.2013.00074","article-title":"Diminished exercise capacity and mitochondrial bc1 complex deficiency in tafazzin-knockdown mice","volume":"4","author":"Powers","year":"2013","journal-title":"Front Physiol."},{"key":"B24","doi-asserted-by":"publisher","first-page":"139","DOI":"10.15252\/emmm.201505644","article-title":"Cardiac-specific succinate dehydrogenase deficiency in Barth syndrome","volume":"8","author":"Dudek","year":"2016","journal-title":"EMBO Mol Med."},{"key":"B25","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1038\/nm.3545","article-title":"Modeling the mitochondrial cardiomyopathy of Barth syndrome with induced pluripotent stem cell and heart-on-chip technologies","volume":"20","author":"Wang","year":"2014","journal-title":"Nat Med."},{"key":"B26","doi-asserted-by":"publisher","first-page":"2850","DOI":"10.1016\/j.jacc.2016.09.972","article-title":"The emerging role of metabolomics in the diagnosis and prognosis of cardiovascular disease","volume":"68","author":"Ussher","year":"2016","journal-title":"J Am Coll Cardiol."},{"key":"B27","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1126\/science.abc8861","article-title":"Comprehensive quantification of fuel use by the failing and non-failing human heart","volume":"370","author":"Murashige","year":"2020","journal-title":"Science."},{"key":"B28","doi-asserted-by":"publisher","first-page":"1659","DOI":"10.1161\/RES.0000000000000097","article-title":"Assessing cardiac metabolism: a scientific statement from the american heart association","volume":"118","author":"Taegtmeyer","year":"2016","journal-title":"Circ Res."},{"key":"B29","doi-asserted-by":"publisher","first-page":"e22533","DOI":"10.2196\/22533","article-title":"Treatment of Barth Syndrome by Cardiolipin Manipulation (CARDIOMAN) with bezafibrate: protocol for a randomized placebo-controlled pilot trial conducted in the nationally commissioned Barth syndrome service","volume":"10","author":"Dabner","year":"2021","journal-title":"JMIR Res Protoc."},{"key":"B30","doi-asserted-by":"publisher","first-page":"3464","DOI":"10.3390\/ijms19113464","article-title":"Elucidating the beneficial role of PPAR Agonists in Cardiac Diseases","volume":"19","author":"Khuchua","year":"2018","journal-title":"Int J Mol Sci."},{"key":"B31","doi-asserted-by":"publisher","first-page":"318","DOI":"10.3389\/fphar.2018.00318","article-title":"The effects of PPAR stimulation on cardiac metabolic pathways in Barth syndrome mice","volume":"9","author":"Schafer","year":"2018","journal-title":"Front Pharmacol."},{"key":"B32","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1016\/j.yjmcc.2007.08.020","article-title":"Fenofibrate modulates cardiac and hepatic metabolism and increases ischemic tolerance in diet-induced obese mice","volume":"44","author":"Aasum","year":"2008","journal-title":"J Mol Cell Cardiol."},{"key":"B33","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1093\/cvr\/cvs129","article-title":"Stimulation of glucose oxidation protects against acute myocardial infarction and reperfusion injury","volume":"94","author":"Ussher","year":"2012","journal-title":"Cardiovasc Res."},{"key":"B34","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1093\/cvr\/cvt216","article-title":"Failing mouse hearts utilize energy inefficiently and benefit from improved coupling of glycolysis and glucose oxidation","volume":"101","author":"Masoud","year":"2014","journal-title":"Cardiovasc Res."},{"key":"B35","doi-asserted-by":"publisher","first-page":"108935","DOI":"10.1016\/j.celrep.2021.108935","article-title":"FoxO1 inhibition alleviates type 2 diabetes-related diastolic dysfunction by increasing myocardial pyruvate dehydrogenase activity","volume":"35","author":"Gopal","year":"2021","journal-title":"Cell Rep."},{"key":"B36","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1186\/1750-1172-8-27","article-title":"New clinical and molecular insights on Barth syndrome","volume":"8","author":"Ferri","year":"2013","journal-title":"Orphanet J Rare Dis."},{"key":"B37","doi-asserted-by":"publisher","first-page":"11568","DOI":"10.1074\/jbc.RA119.009037","article-title":"Cardiolipin-induced activation of pyruvate dehydrogenase links mitochondrial lipid biosynthesis to TCA cycle function","volume":"294","author":"Li","year":"2019","journal-title":"J Biol Chem."},{"key":"B38","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1093\/hmg\/ddab254","article-title":"MCU-complex-mediated mitochondrial calcium signaling is impaired in Barth syndrome","volume":"31","author":"Ghosh","year":"2022","journal-title":"Hum Mol Genet."},{"key":"B39","doi-asserted-by":"publisher","first-page":"1694","DOI":"10.1161\/CIRCULATIONAHA.121.053755","article-title":"Loss of mitochondrial Ca(2+) uniporter limits inotropic reserve and provides trigger and substrate for arrhythmias in Barth syndrome cardiomyopathy","volume":"144","author":"Bertero","year":"2021","journal-title":"Circulation."},{"key":"B40","doi-asserted-by":"publisher","first-page":"17","DOI":"10.3389\/fcvm.2018.00017","article-title":"Cardiac-Specific deletion of pyruvate dehydrogenase impairs glucose oxidation rates and induces diastolic dysfunction","volume":"5","author":"Gopal","year":"2018","journal-title":"Front Cardiovasc Med."},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1210\/endocr\/bqab102","article-title":"Tafazzin deficiency reduces basal insulin secretion and mitochondrial function in pancreatic islets from male mice","author":"Cole","year":"2021","journal-title":"Endocrinology."},{"key":"B42","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1161\/CIRCHEARTFAILURE.109.888479","article-title":"Analysis of metabolic remodeling in compensated left ventricular hypertrophy and heart failure","volume":"3","author":"Kato","year":"2010","journal-title":"Circ Heart Fail."},{"key":"B43","doi-asserted-by":"publisher","first-page":"2735","DOI":"10.2337\/db14-1560","article-title":"Increasing Pyruvate dehydrogenase flux as a treatment for diabetic cardiomyopathy: a combined 13C hyperpolarized magnetic resonance and echocardiography study","volume":"64","author":"Le Page","year":"2015","journal-title":"Diabetes."},{"key":"B44","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1016\/j.cjca.2020.02.098","article-title":"The GLP-1 receptor agonist liraglutide increases myocardial glucose oxidation rates via indirect mechanisms and mitigates experimental diabetic cardiomyopathy","volume":"37","author":"Almutairi","year":"2021","journal-title":"Can J Cardiol."},{"key":"B45","doi-asserted-by":"publisher","first-page":"A11800","DOI":"10.1161\/circ.144.suppl_1.11800","article-title":"Inhibition of pyruvate dehydrogenase kinase does not improve cardiac abnormalities in a mouse model of human Barth syndrome","volume":"144","author":"Greenwell","year":"2021","journal-title":"Circulation."},{"key":"B46","doi-asserted-by":"publisher","first-page":"698","DOI":"10.1161\/CIRCULATIONAHA.115.017355","article-title":"The failing heart relies on ketone bodies as a fuel","volume":"133","author":"Aubert","year":"2016","journal-title":"Circulation."},{"key":"B47","doi-asserted-by":"publisher","first-page":"e0151802","DOI":"10.1371\/journal.pone.0151802","article-title":"Metabolomics reveals new mechanisms for pathogenesis in Barth syndrome and introduces novel roles for cardiolipin in cellular function","volume":"11","author":"Sandlers","year":"2016","journal-title":"PLoS ONE."},{"key":"B48","doi-asserted-by":"publisher","first-page":"1178","DOI":"10.1093\/cvr\/cvaa143","article-title":"Ketones can become the major fuel source for the heart but do not increase cardiac efficiency","volume":"117","author":"Ho","year":"2021","journal-title":"Cardiovasc Res."},{"key":"B49","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1016\/j.jacbts.2018.07.006","article-title":"Empagliflozin increases cardiac energy production in diabetes: novel translational insights into the heart failure benefits of SGLT2 Inhibitors","volume":"3","author":"Verma","year":"2018","journal-title":"JACC Basic Transl Sci."},{"key":"B50","doi-asserted-by":"publisher","first-page":"1931","DOI":"10.1016\/j.jacc.2019.01.056","article-title":"Empagliflozin ameliorates adverse left ventricular remodeling in nondiabetic heart failure by enhancing myocardial energetics","volume":"73","author":"Santos-Gallego","year":"2019","journal-title":"J Am Coll Cardiol."},{"key":"B51","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1016\/j.jacbts.2020.02.004","article-title":"Mechanisms of cardiovascular benefits of sodium glucose Co-transporter 2 (SGLT2) inhibitors: a state-of-the-art review","volume":"5","author":"Lopaschuk","year":"2020","journal-title":"JACC Basic Transl Sci."},{"key":"B52","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1152\/physrev.1980.60.1.143","article-title":"Physiological roles of ketone bodies as substrates and signals in mammalian tissues","volume":"60","author":"Robinson","year":"1980","journal-title":"Physiol Rev."},{"key":"B53","doi-asserted-by":"publisher","first-page":"8748","DOI":"10.1016\/S0021-9258(17)47216-4","article-title":"Binding of the enzymes of fatty acid beta-oxidation and some related enzymes to pig heart inner mitochondrial membrane","volume":"259","author":"Sumegi","year":"1984","journal-title":"J Biol Chem."},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1007\/s10557-022-07320-4","article-title":"Branched-Chain amino acid metabolism in the failing heart","author":"Karwi","year":"2022","journal-title":"Cardiovasc Drugs Ther."},{"key":"B55","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1016\/j.nbd.2009.07.023","article-title":"Mice deficient in dihydrolipoyl succinyl transferase show increased vulnerability to mitochondrial toxins","volume":"36","author":"Yang","year":"2009","journal-title":"Neurobiol Dis."},{"key":"B56","doi-asserted-by":"publisher","first-page":"1110","DOI":"10.1161\/CIRCULATIONAHA.111.060368","article-title":"Metabolomic profiling for the identification of novel biomarkers and mechanisms related to common cardiovascular diseases: form and function","volume":"126","author":"Shah","year":"2012","journal-title":"Circulation."},{"key":"B57","doi-asserted-by":"publisher","first-page":"1680","DOI":"10.1038\/s41467-021-21962-2","article-title":"Branched-chain alpha-ketoacids are preferentially reaminated and activate protein synthesis in the heart","volume":"12","author":"Walejko","year":"2021","journal-title":"Nat Commun."},{"key":"B58","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1007\/s10545-012-9486-x","article-title":"Substrate metabolism during basal and hyperinsulinemic conditions in adolescents and young-adults with Barth syndrome","volume":"36","author":"Cade","year":"2013","journal-title":"J Inherit Metab Dis."},{"key":"B59","doi-asserted-by":"publisher","first-page":"2029","DOI":"10.1111\/bph.12461","article-title":"First-in-class cardiolipin-protective compound as a therapeutic agent to restore mitochondrial bioenergetics","volume":"171","author":"Szeto","year":"2014","journal-title":"Br J Pharmacol."},{"key":"B60","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1038\/s42003-020-1101-3","article-title":"The cardiolipin-binding peptide elamipretide mitigates fragmentation of cristae networks following cardiac ischemia reperfusion in rats","volume":"3","author":"Allen","year":"2020","journal-title":"Commun Biol."}],"container-title":["Frontiers in Cardiovascular Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcvm.2022.981972\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,8,10]],"date-time":"2022-08-10T01:45:39Z","timestamp":1660095939000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcvm.2022.981972\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8,10]]},"references-count":60,"alternative-id":["10.3389\/fcvm.2022.981972"],"URL":"https:\/\/doi.org\/10.3389\/fcvm.2022.981972","relation":{},"ISSN":["2297-055X"],"issn-type":[{"value":"2297-055X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,8,10]]},"article-number":"981972"}}